EPS (Diluted) for Incyte (INCY)
According to Incyte's latest reported financial statements, the company's current diluted EPS (TTM) is $7.08. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
INCY
Currently viewingEPS (Diluted)Switch metric
TTM (last 4 quarters)
$7.08
YoY change
+4173.3%
5Y CAGR
N/A
Peak year (2025)
$6.41
Latest annual
$6.41
EPS (Diluted) history chart for Incyte (INCY) from 1993 to 2025
EPS (Diluted) history table for Incyte (INCY) from 1993 to 2025
| Fiscal year | Period ended | Reported | EPS (Diluted) | YoY |
|---|---|---|---|---|
| 2025 | $6.41 | +4173.3% | ||
| 2024 | $0.15 | -94.3% | ||
| 2023 | $2.65 | +74.3% | ||
| 2022 | $1.52 | -64.4% | ||
| 2021 | $4.27 | -414.0% | ||
| 2020 | $-1.36 | -166.3% | ||
| 2019 | $2.05 | +302.0% | ||
| 2018 | $0.51 | -133.3% | ||
| 2017 | $-1.53 | -383.3% | ||
| 2016 | $0.54 | +1700.0% | ||
| 2015 | $0.03 | -110.3% | ||
| 2014 | $-0.29 | -48.2% | ||
| 2013 | $-0.56 | +64.7% | ||
| 2012 | $-0.34 | -77.2% | ||
| 2011 | $-1.49 | +473.1% | ||
| 2010 | $-0.26 | -87.4% | ||
| 2009 | $-2.06 | +3.5% | ||
| 2008 | $-1.99 | +93.2% | ||
| 2007 | $-1.03 | +15.7% | ||
| 2006 | $-0.89 | -28.2% | ||
| 2005 | $-1.24 | -43.9% | ||
| 2004 | $-2.21 | -5.2% | ||
| 2003 | $-2.33 | +14.8% | ||
| 2002 | $-2.03 | -26.7% | ||
| 2001 | $-2.77 | +489.4% | ||
| 2000 | $-0.47 | -2.1% | ||
| 1999 | $-0.48 | -900.0% | ||
| 1998 | $0.06 | -53.8% | ||
| 1997 | $0.13 | -176.5% | ||
| 1996 | $-0.17 | -45.2% | ||
| 1995 | $-0.31 | -24.4% | ||
| 1994 | $-0.41 | +115.8% | ||
| 1993 | $-0.19 | — |
EPS (Diluted) values are taken from Incyte's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Incyte (INCY) reported diluted EPS of $6.41 – surged 4173.3% year-over-year.
Across 2015–2025 (10 years), Incyte diluted EPS produced a CAGR of +71.0% – with the latest reading among the more recent periods of the dataset.
Across the available history, diluted EPS reached its high of $6.41 in 2025 and its low of $-2.77 in 2001.
Within Healthcare, Incyte (INCY) ranks 8th among 8 peers we track. The peer median for diluted EPS is $13.16.
Incyte EPS (Diluted) by Year
Incyte EPS (Diluted) 2025: $6.41
Incyte diluted EPS in 2025 was $6.41, surged 4173.3% from 2024. This figure represents the highest annual value in the available history.
Incyte EPS (Diluted) 2024: $0.15
Incyte diluted EPS in 2024 was $0.15, plunged 94.3% below 2023.
Incyte EPS (Diluted) 2023: $2.65
Incyte diluted EPS in 2023 was $2.65, surged 74.3% from 2022.
Incyte EPS (Diluted) 2022: $1.52
Incyte diluted EPS in 2022 was $1.52, plunged 64.4% below 2021.
Incyte EPS (Diluted) 2021: $4.27
Incyte diluted EPS in 2021 was $4.27.
See more financial history for Incyte (INCY).
Sector peers — EPS (Diluted)
Companies in the same sector as Incyte, ranked by their latest diluted EPS.
| Company | EPS (Diluted) | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $23.03 | Healthcare |
| Eli Lilly and Company (LLY) | $22.95 | Healthcare |
| Amgen Inc. (AMGN) | $14.23 | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $13.23 | Healthcare |
| AstraZeneca PLC (AZN) | $13.08 | Healthcare |
| Johnson & Johnson (JNJ) | $11.03 | Healthcare |
| Merck & Co., Inc. (MRK) | $7.28 | Healthcare |
| AbbVie Inc. (ABBV) | $2.37 | Healthcare |
Frequently asked questions
What is Incyte's diluted EPS?
- Latest reported diluted EPS for Incyte (INCY) is $7.08 (period ending March 31, 2026).
How has Incyte diluted EPS changed year-over-year?
- Incyte (INCY) diluted EPS changed +4173.3% year-over-year on the latest annual filing.
What is the long-term growth rate of Incyte diluted EPS?
- Incyte (INCY) diluted EPS compound annual growth rate is +71.0% over the most recent 10 years available.
When did Incyte diluted EPS hit its highest annual value?
- Incyte diluted EPS reached its highest annual value of $6.41 in 2025.
What was Incyte diluted EPS in 2024?
- Incyte (INCY) diluted EPS in 2024 was $0.15.
What was Incyte diluted EPS in 2025?
- Incyte (INCY) diluted EPS in 2025 was $6.41.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
INCY Overview
Company profile, financial tools, and key metrics
INCY Revenue Counter
Earns $163.03 every second. See per minute, hour, and day.
INCY Earnings Counter
Earns $40.80 per second net profit. See per minute, hour, and day.
INCY Economic Scale
Exceeds Eswatini's GDP. Compare with world economies.
INCY What If Invested
What if you had invested $1,000? See historical returns from any date.
INCY How It Makes Money
Discover visual breakdown of $5.14B in revenue — where it comes from and where it goes.
INCY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
INCY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
INCY Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
INCY Buybacks
0.10% TTM buyback yield. Shareholder yield & SBC comparison.
INCY Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.